Chronic alcoholism destroys the propensity for hepatic detoxification of toxic substances, which further promotes the rapid and intense accumulation of aldehydes in the liver. Subsequently, chronic alcoholism exerts fatal liver and cardio-renal injury caused by fat deposition, dyslipidemia, inflammation and oxidative stress. The consequence becomes more perilous in disulfiram (potent aldehydes dehydrogenase inhibitor)-allied alcoholism, which further increases hepatic aldehyde accumulation by inhibiting aldehyde dehydrogenase. Ficus benjamina (F. benjamina) is rich in phenolic and total flavonoid content and demonstrates effective antioxidant, anti-inflammatory, antinociceptive, antipyretic, hypotensive, anti-dysentery and antimicrobial properties. Numerous formulations of Ficus benjamina solid lipid nanoparticles (FBSLNP) were prepared and characterized using several physicochemical and drug stability parameters including entrapment efficiency, particle size, zeta potential, and TEM and in vitro drug release studies. In vivo evaluation of FBSLNP was carried out against hepatic and cardio-renal injury induced by concurrent administration of alcohol and disulfiram. Imperative recoveries in studies involving biological parameters including SGPT/SGOT, alkaline phosphatase level, lipid profile, serum protein and oxidative stress, and histological photomicrography revealed the hepatoprotective action of FBSLNP. Reduced levels of accumulated aldehydes in liver tissue were observed via gas chromatography, which confirmed the detoxifying nature of FBSLNP. Moreover, the restoration of aberrant cardio-renal biomarkers (CKMB, LDH, cTnI and serum creatinine, blood urea nitrogen, and microproteinuria) and histological consequences significantly reveal the cardio-renal protective potential of FBSLNP against alcohol abuse/antabuse-associated injury. Considering the results, it may conclude that the significant protection by FBSLNP is based on its anti-oxidant, anti-inflammatory and detoxification potential with regard to accumulated hepatic aldehydes.
Introduction
Alcohol is a psychoactive drug that can result in dependence. A WHO report (2014) disclosed that alcoholism has a high mortality rate of about 3.3 million worldwide and creates a huge global burden on health.
1,2 More specically, chronic alcoholism provokes life-threatening liver diseases including steatosis, brosis, hepatocellular carcinoma, and cirrhosis. In addition, chronic alcoholism has been found to be a primary cause of cardiovascular and renal injury. 3, 4 Conversely, the human body has the ability to metabolize the consumed alcohol into aldehydes in the presence of alcohol dehydrogenase enzyme. The aldehydes produced trigger the impairment of proteins, enzymes, as well as DNA, and thus encourage mutagenesis and brogenesis in the liver. Conventionally, aldehydes can be metabolized to carboxylic acids by the aldehyde dehydrogenase enzyme. These acids are eliminated from the body, but with a slow metabolism rate.
1 Slow metabolism of aldehydes leads to accumulation of aldehydes in hepatic tissue. This accumulation signicantly rises in the presence of disulram, which is a potent aldehyde dehydrogenase inhibitor. Accumulated aldehydes in hepatic tissue considerably increase the prevalence of hepatitis and liver necrosis. Thus, the consequence of liver damage becomes more severe in persons who try to abstain from the consumption of alcohol using antabuse (disulram). 5, 6 This alcohol/aldehyde accumulation or delayed clearance due to enzymatic diminution by disulram causes double toxicity to the liver.
Ficus benjamina (F. benjamina) is a owering plant (family Moraceae) found in India, Malaysia and Australia. This plant is rich in phenolic (chlorogenic, p-coumaric, ferulic and syringic acids), and avonoids compounds which exhibits effective antioxidant, anti-inammatory, antinociceptive, antipyretic, hypotensive, anti-dysentery and antimicrobial properties. 7, 8 Moreover, F. benjamina is also a rich source of alkaloids, triterpenes, and ascorbic acid. 9 Indeed, with its various constituents having potent therapeutic applications, F. benjamina may play a signicant role in hepatoprotection, renal protection and cardiovascular protection. 10 However, high dose of F. benjamina has been reported to cause sub-acute toxicity in liver aer administration for prolonged duration.
11 Nano-formulations with particle sizes more than 60 nm cannot be uptaken by the reticuloendothelial (RES) system when administered by the intravenous route. Thus, conventional nanocarriers are promptly cleared from the circulatory system following intravenous injection ($90%) by RES organs, predominantly by xed macrophages present in the liver. Solid lipid nanoparticles (SLNP) are an alternative colloidal carrier material generated by submicron-sized lipid emulsions. 12 They have unique properties such as smaller sizes, larger surface areas, high drug loading capacity and high phase interaction ability at interfaces, which can potentially improve the performance of therapeutic formulations and signicantly reduce the effective dose concentration. 12 Moreover, being lipophilic in nature, they increase the possibility of RES uptake; hence, an improved localization of a given drug at the target site can be achieved by SLNP. Thus, SLNP of F. benjamina (even in low dose) is enough to produce potential effect that can signicantly overcome subacute toxicity. The present study is focused on the preparation, characterization and in vitro/in vivo evaluation of SLNP of F. benjamina against hepatic and cardio-renal toxicity induced by the individual or co-administration of alcohol abuse and antabuse (disulram).
Material and methods

Collection and identication of F. benjamina
The leaves of F. benjamina plant were collected from the medicinal herb garden, Amity University, Noida, India and were authenticated by Dr M. P. Sharma, Department of Botany, Jamia Hamdard University, Delhi, by comparing sample leaves against a voucher specimen.
Preparation of F. benjamina extract
Fresh leaves of F. benjamina were collected and washed with cold water and then distilled water. The leaves were cut into small pieces and shade dried at room temperature. Furthermore, 80 g of the dried leaves were crushed to form a ne powdered and were extracted using ethanol (2.850 L) at 79 C for 24 h and ltered through Whatman lter paper (no. 1).
Preformulation screening of F. benjamina extract
Preformulation evaluation including melting point (MP, measured using an oil immersion melting point apparatus), solubility (SL, studied by using different solutions to nd out the suitable carrier for the formulation), partition co-efficient (PC) and FTIR (for determination of the physicochemical properties of the extract, including drug and excipient interaction study) were evaluated for F. benjamina extract.
(1) Predetermined samples of F. benjamina (10 mg) were each dissolved in 10 mL of different solvents (water, methanol, ethanol, acetone, chloroform, and benzene; pH adjusted to 7.4 with phosphate buffered saline (PBS), and 0.1 M HCl), to obtain samples of 1 mg mL À1 concentration. Serial dilutions of these solutions of 10, 20, 30, 40, 50, 60, 70, 80, 90 , and 100% were developed, and calibration graphs were generated.
(2) For our solubility study, excess samples were dissolved in the solvents of different polarities until saturated solutions were achieved. The samples were allowed to equilibrate over 24 h. Then, 1 mL of each sample was taken and diluted into 10 mL of solvent, and the amount of drug dissolved in the solvent was calculated by interpolation of the calibration graph.
The partition co-efficient (PC) of the sample was determined by dissolving 10 mg in 40 mL of a 1 : 1 solution of water : noctanol. The sample was continuously stirred using a magnetic stirrer for 2 h. Furthermore, 10 mL of the aqueous phase was withdrawn and the amount of sample dissolved in the aqueous phase was determined by UV-vis spectroscopy and interpolation of the calibration graph.
Moreover, FTIR spectroscopy was carried out using the KBr press pellet technique for determining the physicochemical properties of the extract including drug:excipient interaction study. The F. benjamina extract and sample of excipients were analyzed via FTIR spectroscopy and compared with the FTIR spectra of the drug:excipient combination (the drug and excipients were stored for 3 months at ambient temperature and humidity conditions).
Preparation of F. benjamina solid lipid nanoparticle (FBSLNP)
FBSLNP were prepared by hot-homogenization, followed by ultra-sonication. The ingredients used for the formulation included stearic acid (lipid base), soy-lecithin (surfactant) and de-ionized water (dispersion medium). Briey, the embedded lipid (lipid with entrapped F. benjamina) was melted by heating to 10 C (above melting point of lipid). Conversely, an aqueous phase was prepared by dissolving the soy-lecithin (stabilizer) in distilled water at 10 C. The hot aqueous phase was mixed with the oil phase and homogenized at 25 000 rpm for 10 minutes. This emulsion was sonicated using an ultrasonicator (Life Care Equipments Pvt. Ltd) for 30 minutes and nally the product was allowed to cool at room temperature and FBSLNP suspension was obtained. Lyophilization of the SLNP slurry formulation was carried by lyophilizer (MRCLAB) for 24 h at a temperature of À49 C, and a white powder was collected and stored in desiccators for further evaluation.
2.5 Characterization/evaluation of solid lipid nanoparticles (entrapment efficiency/particle size/zeta potential)
The entrapment efficiency of various formulations of FBSLNP dispersion was determined via a centrifugation method. In brief, SLNP dispersion having 0.5 mL of F. benjamina was centrifuged at 9000 rpm for 30 minutes, and the supernatant was collected. The supernatant was ltered through a Whatman lter paper (grade 1), and the free drug concentration was measured using a UV-spectrometer at 204 nm to determine the entrapment efficiency. Morphological evaluation and measurement of particle size of various formulations were carried out via dynamic light scattering (DLS) using a Malvern Zetasizer instrument (Malvern Instruments, Malvern, UK). The zeta potential was used for determination of the surface charge of the nanoparticles. The zeta potential of various formulations of FBSLNS were determined by the measurement of electrophoretic light scattering (ELS) in the Zetasizer instrument. The samples were prepared by dilution with ultra-pure water and analyzed at 25 C.
2.6
In vitro drug release studies of SLNs 2.6.1 Determination of l max . For the determination of l max , 10 mg of the F. benjamina extract was dissolved in freshly prepared PBS. The solution was scanned using UV-vis spectrophotometry for determination of l max . Serial dilutions of the solution were prepared, and the calibration graph was plotted.
In vitro release study was performed on freshly prepared FBSLNP. Furthermore, 2 mL of dispersion was transferred to a dialysis bag, introduced into a beaker containing 900 mL of a phosphate buffer solution at 37 AE 1 C and stirred at 100 rpm. 
Transmission electron microscopy (TEM)
TEM was carried out for selected formulations to determine the internal properties of the prepared nanoparticles. The samples were prepared by diluting 1 mL of FBSLNP dispersion with 10 mL of pH 7.4 phosphate buffer and were centrifuged at 4000 rpm for 5 minutes. They were then sent to IIT Roorkee for further evaluations for particle size and morphological evaluations of the prepared FBSLNP.
In vivo study
FBSLNP was evaluated against alcohol and disulram-induced hepatic, cardiac and renal toxicity. 2.8.1 Induction and assessment of alcohol and disulram-induced toxicity (hepatic, cardiac and renal toxicity) in rats. Animals were routinely exposed to chronic alcoholism (ethanol, 16 g per kg per day, p.o) for 4 weeks, 13 followed by administration of a potent aldehyde dehydrogenase inhibitor (disulram, 12.5 mg per kg per day, p.o) 14 to induced hepatic toxicity due to direct exposure of alcohol to the liver and deposition of aldehyde in hepatic cells. Deposition of aldehyde in hepatic cells was estimated by a headspace gas chromatography (GCHS) technique. This chronic exposure to alcohol and disulram caused signicant renal and cardiovascular abnormality. Hepatic and cardio-renal toxicity was induced in alcoholic rats over a duration of 4 weeks, the extents of which were measured by estimating various biochemical and histological parameters.
2.8.2 Experimental protocol. The experimental protocol was designed by categorizing the animals into eight groups containing eight rats each. Group 1 (normal control group) animals received blank SLNP, (50 mg per kg per day, p.o (having no drug molecule)) throughout the entire study duration, and group 2 (alcohol treated group) received alcohol (16 g The animal protocol for the present study was approved by IAEC (IAEC/1107/ADH/089) as per the norm of CPCSEA, New Delhi, India. Adult Wistar albino rats (250-300 g of either sex) were obtained from the institutional animal house and acclimatized at normal laboratory conditions (25 AE 1 C temperature; 45-55% relative humidity and normal day/night cycle) for 15 days prior to the start of the experiment. Standard rat food and water was supplied to the animals ad libitum. 2.8.3 Assessment of biochemical parameters. Blood was collected (from the tail vein) from all the animal groups and was allowed to clot at room temperature; serum was separated by centrifugation at 2500 rpm for 15 min. The serum was used for estimation of biochemical parameters to determine the functional state of the liver. Serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT) and alkaline phosphatase (ALP) were measured using commercially available kits (Sigma-Aldrich, US). 15 All other biochemical factors including lipid prole (total cholesterol, triglyceride and high-density lipoprotein) and serum protein were assessed using commercially available kits (Sigma-Aldrich, US). Protein estimation was carried out by measuring albumin and total protein. Hepatic thiobarbituric acid reactive species (TBARS) and reduced glutathione (GSH) were quantied for oxidative stress determination. Creatinine kinase MB (CKMB), lactate dehydrogenase (LDH), cardiac troponin I (cTnI) and serum creatinine, blood urea nitrogen (BUN), and microproteinuria were measured for estimating the cardiovascular and renal damage, respectively, using commercially available kits (Sigma-Aldrich, US).
analyzer) was used to detect the accumulated hepatic alcohol and acetaldehyde. The homogenized liver tissue sample was weighed (1 g) and diluted Â10 with phosphate buffer. Furthermore, 100 mg of supernatant was transferred to head space vials. The screw cap was closed aer adding 2 mL of water. Samples were prepared in duplicate fashion. Quantication was carried out using a ame ionization detector (200 C) with nitrogen as the carrier gas (mobile phase; ow: 0.5 mL min À1 ).
2.8.5 Histological examination. Aer termination of the experimental protocol, animals from each group were sacriced. The vital organs (liver, heart and kidney) were dissected out and were stored in 10% neutral formalin solution embedded in paraffin wax. The sections obtained aer staining with hematoxylin and eosin for 20-40 minutes were observed under an inverted microscope (Cosmo Laboratory Equipment).
2.8.6 Statistical analysis. Statistical analysis was carried out using one-way ANOVA, followed by Tukey's multiple comparison tests (Sigma Plot version 11.0, from Systat Soware, Inc., San Jose California USA). All values were expressed in mean AE SD. ***P < 0.001, **P < 0.01, vs. normal control, @@@ P < 0.001, @@ P < 0.01, vs. alcohol treated, ### P < 0.001, ## P < 0.01, vs.
disulram treated, $$$ P < 0.001, $$ P < 0.01 vs. disulram + alcohol treated were consider as statistical signicant data.
Results
Evaluation of preformulation of F. benjamina extract
The physicochemical properties of the extract including melting point (MP), solubility (SL), and partition co-efficient (PC) are given in Table 1 . FTIR spectra of F. benjamina extract (Fig. 1A ) and excipients samples (Fig. 1B) and their combination (Fig. 1C ) stored for 3 months at room temperature and humid conditions (25 C AE 2 C, RH 60% AE 5%) were analyzed. The analyzed spectra of the stored combined sample of drug and excipients showed no new peaks compared to the F. benjamina extract FTIR spectra of each component, which indicates the absence of new products and conrms the product compatibility with no interactions with each other, as shown in Fig. 1A -C.
Preparation of FBSLNP
Various formulations with different compositions of ingredients were developed, as shown in Table 2 .
3.3 Evaluation of solid lipid nanoparticles (entrapment efficiency/particle size/zeta potential)
Entrapment efficiency plays a crucial role in determining the method of preparation and composition of a formulation. In order to obtain optimum entrapment efficiency, various compositions were evaluated. The entrapment efficiency of all compositions ranged from 68-93%, whereas formulation FE had the highest entrapment efficiency, as shown in Fig. 2A .
Morphological evaluation and particle size determination are essential parameters for conrming the production of nanosize particles. The individual nanoparticle size of FBSLNP from different formulations was measured by DLS and found to be in the range of 44 to 403 nm as depicted in Fig. 2A . Specically, the FE formulation of FBSLNP was found to have the smallest particle size compared to the other formulations.
In addition, the surface potential of nanoparticles is a crucial parameter for stability within biological systems which may lies in between AE30 mV charges for better stability and compatibility. The measured zeta potential (z-potential) of various formulations of FBSLNP are shown in Fig. 2A , which denes the negative surface charge ranging between À25.6 and À39.4 mV. Again, FE formulation of FBSLNP showed a desired zeta potential of À32.7 mV.
In vitro drug release studies of FBSLNP
An alkaline medium, PBS (pH 7.5) was used as the diffusion medium to study the release patterns between different FBSLNS formulations. The maximum percentage in cumulative drug release (% CDR) for all FBSLNP formulations was in the range of 76% to 89%. In the prepared SLNP, the lecithin : stearic acid ratio slightly inuenced the release rate of SLNP because lecithin and stearic acid ratio might change the polymorphic state of lipid constitutes, inducing a difference in catalyzes solubility in lipid matrix, and change drug incorporation. The highest cumulative release was found in the FE formulation during a 12 h time period, as shown in Fig. 2B .
Formulation selection for in vivo study
Selection of more appropriate formulations of FBSLNP for further in vivo analysis was carried on the basis of entrapment efficiency, particle size and zeta potential, which are the prime factors for stability and therapeutic efficacy of nanoformulations. Formulation FE exhibited more favourable measurements for these crucial parameters. Moreover, the in vitro drug release pattern further marks the same formulation on the basis of % CDR, and hence was selected for further in vivo evaluation.
TEM analysis of selected formulation of FBSLNP (FE)
TEM is high-denition microscopy based on a focused beam of electrons and provides various signals as per the sample's surface topography and composition. The TEM image (Fig. 2C ) of a selected formulation (FE) of FBSLNP showed that all particles were roughly spherical in shape, with the size ranging from 20 to 50 nm, due to the non-polar nature of stearic acid and possessed a more stable morphology.
3.7
In vivo study 3.7.1 Assessment of SGOT/SGPT and ALP. Assessment of SGOT/SGPT and ALP level was found to be increased in the alcohol and disulram treated animals either individually or in 
Assessment of albumin and total protein.
Levels of albumin and total protein were found to be signicantly reduced in the alcohol and disulram treated animals either alone or in combination. Conversely, the reduced levels of albumin and total protein were extensively increased by FBSLNP treatment against alcohol and disulram treated animals (FBSLNP + alcohol vs. alcohol treated, FBSLNP + disulram vs. disulram treated and FBSLNP + alcohol + disulram vs. alcohol + disulram treated animals), as shown in Fig. 3D and E respectively.
3.7.3 Assessment of oxidative stress. A substantial decrease in the level of hepatic GSH and increase in the level of hepatic TBARS were found in alcohol and disulram treated animals, either alone or in combination, as compared to the control group, which strongly proves the increased level of hepatic reactive oxygen species (ground mediators of several pitfall signaling). FBSLNP per se treatment did not affect any oxidative marker. However, signicant reduction in the malondialdehyde (MDA) level and substantial increase in the GSH level was observed for the FBSLNP treatment, which reveal the antioxidant potential of F. benjamina (Fig. 3F and G respectively) .
3.7.4 Assessment of alcohol and aldehyde in liver cell. The concentration of accumulated aldehyde in the liver was measured in part per million (ppm) by analyzing dened tissue samples using a 7890A GC system containing an Elite-WAX (30 m Â 0.32 mm Â 0.5 mm) capillary column with an auto sampler. GC-HS showed the signicant presence of accumulated acetaldehyde in the alcohol and disulram (in combination) treated animals compared to normal control animals, which clearly revealed the factor responsible for liver damage in the alcohol and disulram treated animals. Administration of FBSLNP signicantly reduced the deposition of acetaldehyde in the alcohol and disulram treated animals either alone or in combination. This reduction in deposited acetaldehyde from the liver reveals the detoxifying property of FBSLNP, as shown in Fig. 3H and I respectively. The concentration of alcohol and acetaldehyde was calculated using the formula:
Alcohol or acetaldehyde (ppm) ¼ (area of sample/average area of standard) Â (dilution of standard/dilution of sample) Â (purity of standard) Â 10 000 3.7.5 Assessment of serum lipid prole. The lipid prole in serum including total cholesterol, high-density lipoprotein, lowdensity lipoprotein and triglyceride (TC, HDL, LDL and TG) were found to be disrupted in the alcohol and disulram treated animals. TC, LDL and TG were signicantly raised in the alcohol and disulram treated animals either alone or in combination. On the other hand, the HDL level was not signicantly interrupted with the exposure of alcohol and disulram. Interestingly, treatment with FBSLNP reduced the increased level of TC, LDL and TG in the alcohol and disulram treated animals either alone or in combination (Table 3) . Individually, FBSLNP did not show any interaction with the lipid prole.
3.7.6 Assessment of CKMB, LDH and cTnI. Substantially increased levels of CKMB, LDH and cTnI were observed in the alcohol and disulram treated animals either alone or in combination, compared to the control group of animals, which signicantly indicates the presence of cardiac injury. Treatment with FBSLNP considerably decreased their levels compared to the alcohol and disulram treated animals (FBSLNP + alcohol vs. alcohol treated, FBSLNP + disulram vs. disulram treated and FBSLNP + alcohol + disulram vs. alcohol + disulram treated animals) either alone or in combination, as shown in Fig. 4A , B and C, respectively.
3.7.7 Assessment of serum creatinine, BUN, and microproteinuria. Serum creatinine, BUN and microproteinuria are critical biomarkers that indicate renal injury. The levels of serum creatinine and BUN were noted to be signicantly raised in the alcohol and disulram treated animals either alone or in combination, compared to the control animal group that conrmed the existence of renal injury. Furthermore, the incidence of microproteinuria in the alcohol and disulram treated animals either alone or in combination, compared to the control group animals, proved renal damage. However, the treatment with FBSLNP prevented the signicant elevation of serum creatinine and BUN and the occurrence of microproteinuria in the alcohol and disulram treated animals (FBSLNP + alcohol vs. alcohol treated, FBSLNP + disulram vs. disulram treated and FBSLNP + alcohol + disulram vs. alcohol + disulram treated animals) either alone or in combination, as shown in Fig. 4D, E and F respectively. 3.7.8 Histological assessment (liver, heart and kidney respectively). Histological examination of rat liver from the normal control did not show any structural alteration in hepatic lobule from the central vein and hepatic cords. Conversely, swelling of hepatocytes, Kupffer cell activation, karyomegaly, portal inltration with inammatory cells, dysplasia of the bile duct, hyperplasia and hyperactivation of the epithelial lining bile duct were observed in the alcohol and disulram treated animals individually and in combination. All these histological variations were signicantly restored in the FBSLNP treated group against pretreated alcohol and disulram individually and in combination, as shown in Fig. 5(A-1 to A-8) .
The histological section of the normal control rat heart ventricle portion showed no histological lesions. However, the histological examination of diseased group (alcohol and disulram either in alone or in combination) rats showed signicant histological lesions including thrombus formation, myobrillar 
(E), MDA in nano mol mL À1 of hepatic tissue (F), reduced GSH in nano mol g À1 of hepatic tissue (G), alcohol content in ppm per wt of hepatic tissue (H) and aldehyde content in ppm/wt of hepatic tissue (I). All data are expressed as mean AE SD, ***P < 0.001, **P < 0.01, vs. normal control, loss, contraction band necrosis, perivascular cuffing, increased intercalated space (widened intracellular spaces) and nuclei karyolysis in the ventricle photomicrographs. Instead of this, counter treatment of FBSLNP in the alcohol and disulram (either alone or in combination) pretreated animals showed signicant protection in various structural abnormalities.
However, individually, FBSLNP did not show any effect in rat myocardium, as shown in Fig. 5(B-1 to B-8) .
Indeed, alcohol and disulram consumption either alone or in combination lead to glomerulus structural damages including vacuolation of endothelial lining glomerular tus, necrosis of epithelial lining renal tubules, atrophy of the glomerular tu, hypertrophy of the glomerular tu, and a All data are expressed as mean AE SD, ***P < 0.001, **P < 0.01, vs. normal control, @@@ P < 0.001, @@ P < 0.01, vs. alcohol treated, ### P < 0.001, ## P < 0.01, vs. disulram treated, $$$ P < 0.001, vs. disulram + alcohol treated. Fig. 4 The protective role of FBSLNP against individual and combined treatments of alcohol and disulfiram in cardio-renal tissue by measuring
, cTnI concentration in ng mL À1 (C), blood urea nitrogen in mg dL À1 (D), serum creatinine in mg dL À1 (E) and microproteinuria in mg/24 h (F). All data are expressed as mean AE SD, ***P < 0.001, **P < 0.01, vs. normal control, @@@ P < 0.001, 
Discussion
Nanotechnology is an innovative approach in drug formulation, particularly in drug delivery. Certainly, several pathological conditions have been investigated by employing these new drug formulations (nanoparticles) having potent therapeutic action, targeted drug delivery and low toxicity. 17 Moreover, SLNP have fascinating ability to improve plasma stability, biodistribution and subsequent bioavailability of drugs entrapped by altering the surface characteristics of nanoparticles. 18 In addition, SLNP have exceptional admissibility, with nontoxic and biocompatible nature. SLNP are the colloidal drug carrier system equivalent to nanoemulsions, where liquid lipid is replaced by solid lipid at room temperature. 18 Indeed, liver has RES, and hence formation of SLNP of F. benjamina was a suitable approach for targeted delivery. 12, 19 However, high dose of F. benjamina has been reported to cause sub-acute toxicity in a prolonged dosage regimen, and thus a need of an alternative strategy should be considered for desired therapeutic effect. FBSLNP could be a choice for better drug formulation, having higher potency, stability, controlled release and targeted drug delivery to inamed tissue in comparison to the conventional dosage form.
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Evaluation of the physicochemical characteristics of a preformulation of F. benjamina extract explored the melting point, solubility and optimum partition coefficient in octanol/water. Product compatibility was further marked by the absence in drug/excipient interaction aer storage for 3 months at 25 C AE 2 C, 60% RH AE 5%. On the basis of varying ingredients concentration several formulation was composed (eight formulations including: FA, FB, FC, FD, FE, FF, FG and FG) and evaluated for entrapment efficiency, particle size, zeta potential and cumulative drug release (% CDR). Entrapment efficiency is the ratio of the weight of drug entrapped into a carrier system to the total drug added, and it is important to achieve optimal entrapment.
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Moreover, it has been revealed that the morphology of the nanoparticles should be spherical, which would ensure uniformity and less probability of dose dumping. For better bioavailability and therapeutic action, the particle size of the nanoparticles should be less than 100 nm, which would allow easy permeation into body tissues and may produce positive clinical outcomes. Conversely, larger particles may not be engulfed by phagocytes and can cause difficulty in clearance. 18, 22 Moreover, as the pore size of liver fenestrate is about 100 nm, nanoparticles having sizes less than this would be predominantly uptaken by the liver.
23,24 Thus, particle size is a crucial index for size stability in the colloidal dosage form upon storage. Indeed, nanoparticles have larger surface area that facilitate the greater drug release and better bio-distribution. 12, 18 In addition, determination of the zeta potential is another essential factor for determining the physical stability of SLNP for liver targeting. 22 Negatively charged nanoparticles are responsible for electronic stabilization and have more chances of intracellular accumulation in order to potentially target the liver tissue. 23 The observed zeta potential of our prepared nanoformulation was found in the optimal range that can sustain the physical stability of nanoparticles due to the electric repulsion among particles. % CDR is the critical factor for determining drug release in in vivo systems during a 12 h period. On the basis of results obtained in entrapment efficiency (68-93), particle size (range of 44 to 403 nm), zeta potential (À25.6 to À39.4 mV) and % CDR of various formulations (76% to 89%) of FBSLNP, formulation FE (maximum entrapment efficiency, minimum particle size, suitable zeta potential and good % CDR) was selected for further in vivo study. Furthermore, highdenition microscopy based on a focused beam of electrons was carried out for a selected formulation (FE) of FBSLNP and revealed spherically shaped particles with sizes ranging from 20 to 50 nm due to the non-polar nature of stearic acid, which possessed a more stable morphology.
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As a matter of fact, hepatic injury is the most common pathological stage due to the prime site of metabolism and excretion. Chronic exposure to several drugs or junk food could result in liver brosis and cirrhosis. 25 Alcohol is a psychoactive substance, which can result in addiction, and certainly causes toxicity in various organs including the liver, heart and renal tissues. [26] [27] [28] Several clinical and preclinical reports revealed the associated altered biochemical parameters including increased level of SGOT, SGPT, ALP, serum albumin and total protein on chronic alcohol consumption. 26, 28 Similar biochemical alterations were measured in the present study, which conrm alcohol-induced hepatotoxicity. Disulram is a potent irreversible aldehyde dehydrogenase inhibitor, which is clinically known as antabuse across the world. 29, 30 The blockages of aldehyde dehydrogenase enzyme cause signicant rise in aldehyde concentration, which gets accumulated in liver and leads to dual hepatic damage. 30 This was conrmed by measuring the accumulated aldehyde concentration in disulram treated animal liver. Instead of various other chronic adverse drug reactions, aldehyde accumulation in the liver limits its clinical applications. Individual and combined administration of alcohol and disulram strongly perturbed various biochemical parameters including increased level of SGOT, SGPT, ALP, serum albumin, total protein, CKMB, LDH, cTnI, BUN, serum creatinine and microproteinuria, which signicantly endorse the major damage in the liver and cardio-renal system. Moreover, accumulated aldehyde in liver conrmed the associated liver damage. Indeed, increased oxidative stress is another key factor for various organs being damaged. 31 Individual and combined administration of alcohol and disulram resulted in signicant elevation in oxidative stress and associated tissue damage.
The therapeutic potential of herbal drug nanoparticles against alcohol/disulram-induced liver toxicity remains an area for extensive scientic research. The current preclinical study provides substantial evidence of signicant hepatoprotective potential of FBSLNP measured by restoration of altered biochemical parameters. SGOT, SGPT and ALP enzymes are highly sensitive serum biomarkers which directly represent the extent of hepatic damage. 32 Moreover, FBSLNP signicantly detoxify the accumulated aldehyde from liver measured by GC-HS. Similarly, serum albumin and total protein levels were signicantly increased by the treatment of FBSLNP. Substantial diminution of hepatic MDA and increased level of reduced GSH conrmed the anti-oxidant potential of FBSLNP. Hence detoxication of accumulated aldehyde from the liver and the antioxidant potential of FBSLNP may be consider to be the possible mechanism of liver protection against alcohol/ disulram-induced hepatotoxicity. Histological outcomes further conrmed the structural restoration of liver tissue by FBSLNP treatment, as compared to alcohol/disulram treated animals.
High intake of alcohol with or without disulram treatment causes cardio-renal injury due to depletion of ATP and electron leakage from the respiratory chain.
5 These free electrons combine with molecular oxygen and generate ROS. 31 ROS can oxidize protein, DNA and membrane lipids and lead to cardiorenal damage. ROS mediated disruption may increase the release of CKMB, LDH and cTnI enzyme into the serum. 16, 31, 33 Furthermore, increased ROS concomitantly decreases the work functionality of renal system. 16, 33 Altered glomerular ltration rate or deterioration in renal function was reected by the increase in BUN and creatinine, as well as the occurrence of microproteinuria. 16, 33 The alcohol/disulram-induced deleterious effects on the renal system were indicated by the increased level of serum BUN, creatinine and the occurrence of microproteinuria. Cardio-renal protection was evident from the improved structural and functional parameters of the heart and kidney tissues. Aberrant cardio-renal biomarker levels were signicantly restored by FBSLNP treatment in alcohol/ disulram treated animals.
In conclusion, the present study showed that FBSLNP is an appropriate formulation for targeted drug delivery to the liver, as revealed by entrapment efficiency, particle size, surface charge and in vitro release. F. benjamina has signicant ability to detoxify the accumulated aldehyde in the liver, which is accumulated due to chronic alcoholism and disulram treatment. FBSLNP restored the structural and functional parameters of hepatic and cardio-renal tissues that were distorted by alcohol/ disulram administration. This constructive effect of FBSLNP to ameliorate alcohol/disulram-induced hepatic and cardiorenal toxicity may be due to their potential to detoxifying the accumulated aldehyde in the liver as well as their signicant anti-oxidant, anti-inammatory and anti-apoptotic effects. 
